M2 Group Revenue and Competitors
Estimated Revenue & Valuation
- M2 Group's estimated annual revenue is currently $36.1M per year.
- M2 Group's estimated revenue per employee is $325,000
Employee Data
- M2 Group has 111 Employees.
- M2 Group grew their employee count by -2% last year.
M2 Group's People
Name | Title | Email/Phone |
---|
M2 Group Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7664.5M | 16845 | N/A | N/A | N/A |
#2 | $6.1M | 27 | N/A | N/A | N/A |
#3 | $35.1M | 108 | N/A | N/A | N/A |
#4 | $2.3M | 12 | N/A | N/A | N/A |
#5 | $39.3M | 121 | N/A | N/A | N/A |
#6 | $55.4M | 155 | N/A | N/A | N/A |
#7 | $3.3M | 17 | N/A | N/A | N/A |
#8 | $422.7M | 929 | N/A | N/A | N/A |
#9 | $9.4M | 36 | N/A | N/A | N/A |
#10 | $17.8M | 61 | -5% | N/A | N/A |
What Is M2 Group?
This company page is no longer active, following M2 Group Ltd's merger with Vocus Group Limited in February 2016. Please follow us on the Vocus page for company information: https://www.linkedin.com/company-beta/16233137/
keywords:N/AN/A
Total Funding
111
Number of Employees
$36.1M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
M2 Group News
2022-04-17 - Placental mesenchymal stem cells boost M2 alveolar over M1 ...
(I, J) Pooled data for analyses of frequency and absolute number of resident AM?s in lung lobes of each experimental group, respectively (n=8...
2022-04-17 - Second-Line Anetumab Ravtansine Yields Manageable ...
Patients received 30 mg/m2 once every week of vinorelbine through an ... At the data cutoff, 105 patients in the anetumab ravtansine group...
2022-04-06 - Apple tests several new Macs with next-generation M2 chips ...
The company is testing at least nine Mac models with four different M2-based chips - the successors to the current M1 line - with...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $17.8M | 111 | 25% | N/A |
#2 | $16.1M | 111 | -1% | N/A |
#3 | N/A | 111 | 9% | N/A |
#4 | $30M | 111 | -12% | N/A |
#5 | $15M | 111 | 8% | N/A |